Saturday, April 27, 2024, Washington, DC, 12:15 PM – 1:45 PM Eastern Time

What I Tell My Patients: Integrating New Research Information into Current Clinical Care

A Complimentary NCPD Hybrid Symposium Series Held During the 49th Annual ONS Congress


Marriott Marquis Washington, DC
901 Massachusetts Avenue NW
Washington, DC 20001
Hotel Phone: (202) 824-9200

Program Schedule — Eastern Time
11:45 AM – 12:15 PM — Registration
12:15 PM – 1:45 PM — NCPD Lunch Meeting

Meeting Room
Independence Ballroom (Meeting Level 4)

This event will also be webcast live.
Please see Registration tab for details.

There is no registration fee for this event. For the in-person symposium in Washington, DC, preregistration is required as seating is limited.  
Ilene Galinsky, NP
Senior Adult Leukemia Program Research
Nurse Practitioner
Dana-Farber Cancer Institute
Boston, Massachusetts

Andrew T Kuykendall, MD
Associate Member
Department of Malignant Hematology
Moffitt Cancer Center
Assistant Professor
Department of Oncologic Sciences
University of South Florida
Tampa, Florida

Sara M Tinsley-Vance, PhD, APRN, AOCN
Nurse Practitioner and Researcher
Malignant Hematology
Moffitt Cancer Center
Courtesy Assistant Professor
University of South Florida College of Nursing
Tampa, Florida

Abdulraheem Yacoub, MD
Professor of Medicine
Division of Hematologic Malignancies
and Cellular Therapeutics (HMCT)
Department of Internal Medicine
The University of Kansas Cancer Center
Westwood, Kansas

Neil Love, MD
Research To Practice
Miami, Florida

Meeting space has been assigned to provide a satellite symposium supported by CTI Biopharma, a Sobi company, GSK, and Incyte Corporation during the Oncology Nursing Society’s (ONS) 49th Annual Congress, April 24-28, 2024 in Washington, DC. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.
Program Schedule — Eastern Time
11:45 AM – 12:15 PM — Registration
12:15 PM – 1:45 PM — NCPD Lunch Meeting

What I Tell My Patients About ...

The Biology of Myelofibrosis (MF)

  • Typical presentation, symptoms and clinical course of MF; differences between primary and secondary disease
  • Clinical significance of the JAK-STAT pathway in MF development
  • Appropriate risk stratification for patients with MF; advantages and limitations of available scoring systems
  • Establishing goals of care; identification of patients who may be appropriate for allogeneic stem cell transplant
  • Effectiveness of various interventions, such as transfusions, erythropoiesis-stimulating agents, growth factors and splenectomy, in addressing common symptoms of MF

The Role of Ruxolitinib in Therapy for MF

  • Published research database with ruxolitinib for patients with intermediate- and high-risk MF; impact on symptom control and survival
  • Common side effects and toxicities associated with ruxolitinib, such as thrombocytopenia, anemia, neutropenia and infection; appropriate monitoring of blood counts
  • Initial dosing of ruxolitinib and dose-modification strategies for patients with treatment-related toxicity, preexisting thrombocytopenia or inadequate initial response
  • Importance of gradual tapering versus abrupt discontinuation of ruxolitinib

Fedratinib in the Management of MF

  • Mechanistic similarities and differences between fedratinib and ruxolitinib
  • Efficacy and safety outcomes reported in key studies of fedratinib for newly diagnosed or previously treated MF; selection of patients for fedratinib therapy
  • Incidence of encephalopathy with fedratinib; assessment of thiamine levels and thiamine supplementation for patients receiving this agent
  • Rates of gastrointestinal (GI) adverse events reported with fedratinib; early implementation of mitigation strategies to prevent GI toxicity
  • Spectrum, frequency and severity of other toxicitiesassociated with fedratinib; optimal approach to monitoring and management

The Role of Pacritinib in MF Treatment

  • Implications of the mechanistic differences between pacritinib and other approved JAK inhibitors for its safety in cytopenic patients
  • Key efficacy and safety findings with pacritinib for MF, including for patients with baseline thrombocytopenia
  • FDA approval of pacritinib for patients with MF and severe thrombocytopenia; optimal use in clinical practice and ongoing investigations
  • Potential utility of pacritinib for patients with MF and severe anemia
  • Reported risk of hemorrhage and other adverse events with pacritinib; importance of holding therapy before planned surgical and invasive procedures

The Current Utility of Momelotinib in Therapy for MF

  • Rationale for the activity of momelotinib in patients with MF and anemia
  • Historical data sets with momelotinib for treatment-naïve and previously treated MF
  • Key clinical trial findings supporting the FDA approval of momelotinib for symptomatic, anemic patients with MF
  • Tolerability and toxicity profile of momelotinib; recognitionand management of commonly occurring adverse events, such as anemia, thrombocytopenia, infections and peripheral neuropathy

Targeting Bcl-2 with Navitoclax

  • Mechanism of antitumor activity of navitoclax and biological rationale for its evaluation in patients with MF, including in tandem with JAK2 inhibition
  • Recently presented efficacy and safety findings with navitoclax in combination with ruxolitinib versus ruxolitinib alone for patients with previously untreated MF
  • Potential role of navitoclax in the up-front setting and ongoing evaluation for relapsed/refractory disease
  • Tolerability profile of navitoclax in published clinical investigations

The Potential Role of Bromodomain and Extraterminal (BET) Inhibitors in Therapy for MF

  • Scientific justification for the inhibition of BET proteins in MF; mechanism of action of pelabresib
  • Recently presented findings with the combination of pelabresib and ruxolitinib for JAK inhibitor-naïve MF
  • Early results with and ongoing evaluations of other BET inhibitors, such as INCB057643 and BMS-986158, as monotherapy and in combination with JAK inhibitors

Other Promising Agents and Strategies for Patients with MF

  • Educating patients on the potential advantages of participating in a clinical research study of a novel strategy
  • Available data with luspatercept as monotherapy or combined with a JAK2 inhibitor for patients with MF and anemia; current nonresearch role, if any
  • Potential role of ACVR1/ALK2 inhibition in alleviating anemia in patients with MF; mechanism of action of zilurgisertib
  • Preliminary data with and ongoing investigation of zilurgisertib as monotherapy and combined with ruxolitinib for patients with anemia due to MF
  • Early activity and safety data with and ongoing investigation of other novel agents and strategies for MF, such as imetelstat, navtemadlin, selinexor, bomedemstat and ropeginterferon alfa-2b

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of myelofibrosis (MF).

Learning Objectives
Upon completion of this activity, participants should be able to

  • Use an understanding of disease biology and natural history to effectively counsel patients diagnosed with MF regarding their long-term prognosis.
  • Analyze how age, performance status, prior therapeutic exposure and other biological and disease-related factors affect the selection and sequencing of approved JAK inhibitors for patients with primary and secondary MF.
  • Appraise available research findings informing the safety and efficacy of novel JAK inhibitors for patients with MF and anemia, and understand the rationale for specific treatment recommendations.
  • Review available research data with and the current clinical role of novel JAK inhibitors for patients with MF and severe thrombocytopenia.
  • Develop supportive care plans to more effectively monitor for, identify and manage side effects and toxicities associated with agents commonly used for MF.
  • Increase participation in active research protocols by counseling appropriately selected patients about the biological rationale for and available efficacy and safety data with novel investigational agents and strategies for MF.

Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

ONCC/ILNA Certification
This program will be submitted for ONCC/ILNA certification.

Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Ms GalinskyAdvisory Committees: AbbVie Inc, Astellas, CTI Biopharma, a Sobi company, Novartis, Takeda Pharmaceuticals USA Inc; Consulting Agreements: AbbVie Inc, CTI Biopharma, a Sobi company, Novartis. Dr KuykendallAdvisory Committees: AbbVie Inc, Blueprint Medicines, Bristol Myers Squibb, Cogent Biosciences, CTI Biopharma, a Sobi company, Incyte Corporation, Karyopharm Therapeutics, PharmaEssentia; Consulting Agreements: AbbVie Inc, Karyopharm Therapeutics, MorphoSys; Contracted Research: Blueprint Medicines, Bristol Myers Squibb, Geron, Janssen Biotech Inc, MorphoSys, Protagonist Therapeutics; Data and Safety Monitoring Board/Committee: Geron. Dr Tinsley-VanceAdvisory Committees: AbbVie Inc, CTI Biopharma, a Sobi company, Incyte Corporation, Pfizer Inc; Consulting Agreements: CTI Biopharma, a Sobi company, Incyte Corporation, Novartis; Speakers Bureaus: Astellas, Bristol Myers Squibb, CTI Biopharma, a Sobi company, Incyte Corporation, Jazz Pharmaceuticals Inc; Nonrelevant Financial Relationships (Contracted Research): Gulf Coast Community Foundation, National Institutes of Health, Patient-Centered Outcomes Research Institute. Dr YacoubConsulting Agreements: AbbVie Inc, Acceleron Pharma, Apellis, CTI Biopharma, a Sobi company, Gilead Sciences Inc, Incyte Corporation, Karyopharm Therapeutics, Notable Labs, Novartis, Pfizer Inc, PharmaEssentia, Protagonist Therapeutics, Servier Pharmaceuticals LLC.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME/NCPD activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI Biopharma, a Sobi company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from CTI Biopharma, a Sobi company, GSK, and Incyte Corporation.

Marriott Marquis Washington, DC
901 Massachusetts Avenue NW
Washington, DC 20001
Hotel Phone: (202) 824-9200

Meeting Room:
Independence Ballroom (Meeting Level 4)

The Marriott Marquis Washington, DC is the headquarters hotel for the 2024 ONS Congress and is connected to the Walter E Washington Convention Center by an underground concourse.


This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of myelofibrosis.

There is no registration fee for this event. For the in-person symposium in Washington, DC, preregistration is required as seating is limited.

Registration for this event is independent of registration for the 2024 ONS Congress.

IN-PERSON Registration for nurses and other healthcare providers

I am a practicing nurse or other healthcare provider involved in the treatment of cancer.

IN-PERSON Registration
for clinicians »
IN-PERSON Registration for other/industry professionals*

Please note, a limited number of seats are available to other/industry professionals on a first come, first served basis.

IN-PERSON Registration
for nonclinicians »
* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
LIVE WEBCAST Registration for all professionals

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 15 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.